Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes

Diabetes Care

Volumn 30, Issue 9, 2007, Pages 2242-2244

  Kadoglou, Nikolaos P E ^a,b,e   Iliadis, Fotios ^a   Liapis, Christos D ^b   Perrea, Despina ^c   Angelopoulou, Nikoleta ^d   Alevizos, Miltiadis ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; GLICLAZIDE; METFORMIN; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG MECHANISM; EXERCISE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

AGED; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; EXERCISE THERAPY; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 34548407272     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-0341     Document Type: Article

References (19)

1. Boule NG, Kenny GP, Haddad E, Wells GA, Sigal RJ: Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in type 2 diabetes mellitus. Diabetologia 46:1071-1081, 2003
2. Sigal RJ, Kenny GP, Wassermann DH, Castaneda-Sceppa C, White RD: Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 29:1433-1438, 2006
3. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA: Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134:61-71, 2001
4. Barbier O, Torra P, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B: Pleiotropic actions of peroxisome proliferatoractivated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22:717-726, 2002
5. Kadoglou NP, Perrea D, Iliadis F, Angelopoulou N, Liapis CD, Alevizos M: Exercise reduces resistin and inflammatory cytokines in patients with type 2 diabetes. Diabetes Care 30:719 -721, 2007
6. Wallace MT, Levy CJ, Matthews RD: Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495, 2004
7. McGavock JM, Mandic S, Muhll IV, Lewanczuk RZ, Quinney HA, Taylor DA, Welsh RC, Haykowsky M: Low cardiorespiratory fitness is associated with elevated C-reactive protein levels in women with type 2 diabetes. Diabetes Care 27:320-325, 2004
8. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W, Furnsinn C: Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53:1052-1059, 2004
9. Hallsten K, Virtanen, Lonnqvist F, Sipila H, Oksanen A, Viljanen T, Ronnemaa, Viikari J, Knuuti J, Nuutila P: Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51:3479-3485, 2002
10. Fang ZY, Sharman J, Prins JB, Marwick TH: Determinants of exercise capacity in patients with type 2 diabetes. Diabetes Care 28:1643-1648, 2005
11. Regensteiner JG, Bauer TA, Reusch JEB: Rosiglitazone improves exercise capacity in individuals with type 2 diabetes. Diabetes Care 28:2877-2883, 2006
12. Bogacka I, Xie H, Bray GA, Smith SR: Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54:1392-1399, 2005
13. Lihn AS, Pedersen SB, Richelsen B: Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 6:13-21, 2005
14. Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT: Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 97:646-650, 2006
15. Monzillo LU, Hamdy O, Horton ES, Ledbury, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa, Mantzoros C: Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 11:1048-1054, 2003
16. Jung HS, Youn B-S, Cho YM, Yu K-Y, Park HJ, Shin CS, Kim SY, Lee HK, Pak KS: The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 54:314-320, 2005
17. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR Jr, Willson TM, Kliewer SA, Hotamisligil GS: Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 276:25651-25653, 2001
18. Esposito K, Ciotola M, Carleo D, Schisano B, Saccomano F, Sasso FC, Cozzolino D, Assloni R, Merante D, Cerielo A, Giuglano D: Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29:1071-1076, 2006
19. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684, 2002